iScience · 2021 · 48 citations · 28 references
Life SciencesInfectious DiseasesMolecular BiologyImmunotherapyInnate ImmunityMolecular VirologyAntiviral TherapyProtein TargetingViral InfectionsVirus EntryAntibody-mediated Viral NeutralizationEntry Receptor SpecificityIn Vivo StudiesSars-cov-2 Antiviral TherapySars-cov-2 InfectionTissue BioavailabilityViral Fusion ProteinsViral Spike Proteins
SARS-CoV-2, the etiologic agent of COVID-19, uses ACE2 as a cell entry receptor. Soluble ACE2 has been shown to have neutralizing antiviral activity but has a short half-life and no active transport mechanism from the circulation into the alveolar spaces of the lung. To overcome this, we constructed an ACE2-human IgG1 fusion protein with mutations in the catalytic domain of ACE2. A mutation in the catalytic domain of ACE2, MDR504, significantly increased binding to SARS-CoV-2 spike protein, as well as to a spike variant, in vitro with more potent viral neutralization in plaque assays. Parental administration of the protein showed stable serum concentrations with excellent bioavailability in the epithelial lining fluid of the lung, and ameliorated lung SARS-CoV-2 infection in vivo. These data support that the MDR504 hACE2-Fc is an excellent candidate for treatment or prophylaxis of COVID-19 and potentially emerging variants.
28
Virological assessment of hospitalized patients with COVID-2019
Roman Wölfel, Victor M. Corman, Wolfgang Guggemos et al. · Nature · 2020 · 7.2K citations · Full text
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Jun Lan, Jiwan Ge, Jinfang Yu et al. · Nature · 2020 · 6.7K citations · Full text
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
Renhong Yan, Yuanyuan Zhang, Yaning Li et al. · Science · 2020 · 5.6K citations · Full text